Faster Access to New Medicines: MHRA-NICE Collaboration Speeds Up Approval Process
Patients in the UK will soon receive new medicines up to 6 months earlier under a streamlined MHRA-NICE approval system that synchronizes licensing and value assessments.
In a significant move aimed at improving patient access to innovative treatments, the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have announced a new joint approval process that will shorten the time it takes for new medicines to reach the hands of British patients.
Under the new pathway, the MHRA and NICE will work in close collaboration to synchronize their respective licensing and value assessment decisions, reducing the overall timeline by up to six months. This streamlined approach promises to deliver critical new medicines to the National Health Service (NHS) and, ultimately, to patients much faster than the current sequential process.
{{IMAGE_PLACEHOLDER}}Source: UK Government
